Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV

Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV

Zhan, Xiaoyan, Martin, Louis N., Slobod, Karen S., Coleclough, Chris, Lockey, Timothy D., Brown, Scott A., Stambas, John, Bonsignori, Mattia, Sealy, Robert E., Blanchard, James L. and Hurwitz, Julia L. 2005, Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV, Vaccine, vol. 23, no. 46-47, pp. 5306-5320.

Attached Files (Some files may be inaccessible until you login with your Deakin Research Online credentials)
Name			Description	MIMEType		Size	Downloads

Title	Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV
Author(s)	Zhan, Xiaoyan Martin, Louis N. Slobod, Karen S. Coleclough, Chris Lockey, Timothy D. Brown, Scott A. Stambas, John Bonsignori, Mattia Sealy, Robert E. Blanchard, James L. Hurwitz, Julia L.
Journal name	Vaccine
Volume number	23
Issue number	46-47
Start page	5306
End page	5320
Publisher	Elsevier Ltd.
Place of publication	Guildford, England
Publication date	2005-11-16
ISSN	0264-410X
Keyword(s)	HIV-1 vaccine Pathogenic SHIV Non-human primate Envelope cocktail
Summary	A central obstacle to the design of a global HIV-1 vaccine is virus diversity. Pathogen diversity is not unique to HIV-1, and has been successfully conquered in other fields by the creation of vaccine cocktails. Here we describe the testing of an HIV-1 envelope cocktail vaccine. Six macaques received the vaccine, delivered by successive immunizations with recombinant DNA, recombinant vaccinia virus and recombinant envelope proteins. Following vaccination, animals developed a diversity of anti-envelope antibody binding and neutralizing activities toward proteins and viruses that were not represented by sequence in the vaccine. T-cells were also elicited, as measured by gamma-interferon production assays with envelope-derived peptide pools. Vaccinated and control animals were then challenged with the heterologous pathogenic SHIV, 89.6P. Vaccinated monkeys experienced significantly lower virus titers and better maintenance of CD4+ T-cells than unvaccinated controls. The B- and T-cell immune responses were far superior post-challenge in the vaccinated group. Four of six vaccinated animals and only one of six control animals survived a 44-week observation period post-challenge. The present report is the first to describe pathogenic SHIV disease control mediated by a heterologous HIV-1 vaccine, devoid of 89.6 or SIV derivatives.
Language	eng
Field of Research	110804 Medical Virology
Socio Economic Objective	970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category	C1.1 Refereed article in a scholarly journal
Copyright notice	©Copyright 2005 Elsevier Ltd All rights reserved.
Persistent URL	http://hdl.handle.net/10536/DRO/DU:30028917

Document type:	Journal Article
Collection:	School of Medicine

Citation counts:	Cited 27 times in TR Web of Science Cited 28 times in Scopus
Access Statistics:	271 Abstract Views, 0 File Downloads - Detailed Statistics
Created:	Wed, 26 May 2010, 16:07:24 EST

Deakin Research Online

Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV

Study

Research

Access Deakin

On campus

Connect